Nucleotide laboratory: characterization in GMP environment and impurity control

Home • Biopharmaceuticals analytical services • GMP Nucleotide Laboratory

Addressing the analytical challenges of nucleotides in development and production

The development of products based on nucleotides requires a high level of analytical control at every stage: structural confirmation, purity monitoring, identification of related compounds, investigation of inorganic contaminants, and demonstration of regulatory compliance. For biopharmaceutical manufacturers, these requirements become even more critical in a GMP environment, particularly during transfer, release, investigation, or process qualification phases. A nucleotide laboratory must be able to produce robust, traceable, and actionable data for quality dossiers. In this context, impurity control is not limited to a global measurement: it must include elemental impurities, metal traces, specific compounds to be monitored, and the performance of the analytical methods used.

Identify the critical impurities of the product and the process

Depending on the nature of the nucleotide, its synthesis route, raw materials and manufacturing process, several impurity families may require specific monitoring: substance-related impurities, synthesis by-products, inorganic residues, metal catalysts, solvents or contaminants originating from equipment. Impurity control must therefore be defined on the basis of a risk analysis and the regulatory requirements applicable to the product.

Combine separation, spectrometric and elemental techniques

Nucleotide characterization may require several levels of investigation: structural confirmation, mass determination, purity profiling, search for minor species and contaminant quantification. To achieve this, the laboratory relies on an analytical platform including HPLC, LC-MS/MS, LC-HRMS, GC-MS/MS, ICP-AES, ICP-MS and ICP-MS/MS. This complementarity makes it possible to address both structural issues and trace-level quantification needs.

Benefit from analytical expertise focused on the biopharmaceutical industry

Filab supports manufacturers with complex analytical challenges combining development, characterization, validation and investigation. The laboratory works on pharmaceutical matrices with a results-oriented approach, taking into account constraints related to turnaround time, compliance and transferability. Its expertise covers in particular methods for determining elemental impurities, identifying trace-level compounds and implementing analytical protocols tailored to quality needs.

Rely on a GMP laboratory to characterize, develop and validate

Our laboratory supports biopharmaceutical players in nucleotide characterization, analytical method development and validation according to applicable standards. Our approach is built around your quality objectives: confirming identity, documenting structure, quantifying impurities, defining limits suited to the product, and demonstrating method reliability. Work is carried out within a structured quality framework, with expertise in pharmaceutical analysis, separation techniques, mass spectrometry and trace element determination. To broaden the physicochemical evaluation of your products, you can also explore our approach to material characterization.

Deploy analytical strategies suited to the expected thresholds

The laboratory implements targeted or screening methods depending on the profile required: liquid chromatography coupled with mass spectrometry for organic compounds, ICP-MS, ICP-MS/MS or ICP-AES for elemental impurities, as well as development and validation approaches aligned with pharmaceutical expectations. This approach is particularly useful for the determination of elements covered by ICH Q3D, such as arsenic, lead, cadmium, mercury, nickel, cobalt, vanadium, palladium or platinum.

Adapt the analytical setup to GMP requirements

In a GMP environment, analytical performance must be demonstrated and documented. The laboratory can therefore develop a specific method, optimize it according to the matrix, and then validate it using appropriate criteria: specificity, accuracy, precision, linearity, robustness, detection limits and quantification limits. For broader instrumental characterization needs, you can also discover our expertise in Electrochemical Characterization Analysis or our article dedicated to At The Forefront Of Characterization The Meb Feg.

Move forward with a structured partner for GMP studies

The laboratory relies on an extensive equipment platform, a recognized quality organization and experience with analytical standards in the pharmaceutical sector. This combination makes it possible to support your teams for one-off studies as well as more strategic projects: method development, validation, batch-to-batch comparison, deviation investigation or qualification support. Depending on your needs for control over materials and components, you can also consult our Pmuc Control page.

Define the need, submit the samples, validate the analytical strategy

To start a study, it is necessary to specify the nature of the nucleotide, the matrix, the project context, the target impurities, the expected thresholds, and the desired documentation framework. The laboratory can then propose a suitable analytical strategy: confirm the structure, develop the method, validate performance, quantify impurities, and formalize the results. To move forward efficiently, request a feasibility study, submit your specifications, define the analytical requirements, plan the tests, and receive dedicated technical support.

Frequently asked questions

How can nucleotide characterization be secured in a GMP environment while keeping critical impurities under control?

To secure nucleotide characterization in a GMP environment, you need to combine identity confirmation, structural assessment, targeted impurity testing and analytical method validation. The goal is to obtain traceable and defensible results for development, quality control or investigation.

Which impurities should be monitored for a nucleotide in a biopharmaceutical context?

The impurities to monitor for a nucleotide depend on the process and the intended use of the product, but often include synthesis-related impurities, metallic traces and elemental impurities. A relevant analytical strategy is based on risk analysis, product specifications and regulatory requirements.

What analytical tools should be used to characterize a nucleotide and quantify its impurities?

Characterization of a nucleotide and quantification of its impurities generally rely on a combination of chromatography, mass spectrometry and elemental analysis. The choice of techniques depends on the product structure, the matrix, the target thresholds and the required validation level.

Why entrust these analysis to the Filab laboratory?

Choosing the Filab laboratory means relying on a laboratory capable of handling complex analytical challenges in a GMP environment, with the resources suited to nucleotide characterization and impurity control. Support covers feasibility studies, method development, validation, and the use of results for your quality requirements.

How do you launch a characterization or impurity control study on a nucleotide?

To launch the project, simply share your analytical needs, your GMP constraints, your specifications, and the information available on the product. An analysis strategy tailored to the nucleotide, the impurities targeted, and the expected validation level can then be defined quickly.